Up-regulation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure - A possible link between circulating PCSK9 and triacylglycerol concentrations

Atherosclerosis

Volumn 248, Issue , 2016, Pages 17-26

  Sucajtys Szulc, Elzbieta ^a   Szolkiewicz, Marek ^a   Swierczynski, Julian ^a   Rutkowski, Boleslaw ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

apoB 100; CRF; FASN; HNF1; HNF4; MTP; PCSK9

Indexed keywords

ACETYL COENZYME A CARBOXYLASE 1; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; APOLIPOPROTEIN B100; BETA ACTIN; CHOLESTEROL; CLOFIBRATE; CREATININE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; ELONGASE 6; FATTY ACID SYNTHASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE 1; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; MALATE DEHYDROGENASE (DECARBOXYLATING); MALATE DEHYDROGENASE (DECARBOXYLATING) 1; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; STEAROILO ACETYL COENZYME A DESATURASE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; VERY LOW DENSITY LIPOPROTEIN; ACTIN; CARRIER PROTEIN; HEPATOCYTE NUCLEAR FACTOR 4; HNF1A PROTEIN, RAT; HNF4A PROTEIN, RAT; PCSK9 PROTEIN, RAT; PROPROTEIN CONVERTASE 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVATION; EXPERIMENTAL RENAL FAILURE; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOASSAY; LIPOGENESIS; LIVER; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; UREA BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; BLOOD; BODY WEIGHT; DISEASE MODEL; GENETICS; METABOLISM; WISTAR RAT;

ACTINS; ANIMALS; APOLIPOPROTEIN B-100; BODY WEIGHT; CARRIER PROTEINS; CLOFIBRATE; DISEASE MODELS, ANIMAL; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, VLDL; LIVER; MALE; NEPHRECTOMY; PROPROTEIN CONVERTASE 9; RATS; RATS, WISTAR; RNA, MESSENGER; TRIGLYCERIDES; UP-REGULATION;

EID: 84961878400     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.02.027     Document Type: Article

References (50)

1. Oda H., Keane W.F. Lipid abnormalities in end stage renal disease. Nephrol. Dial. Transpl. 1998, 3(Suppl. 1):45-49.
2. Sun L., Halaihel N., Zhang W., Rogers T., Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J. Biol. Chem. 2002, 277:18919-18927.
3. Konarzewski M., Szolkiewicz M., Sucajtys-Szulc E., Blaszak J., Lizakowski S., Swierczynski J., Rutkowski B. Elevated circulating PCSK-9 concentration in renal failure patients is corrected by renal replacement therapy. Am. J. Nephrol. 2014, 40:157-163.
4. Sucajtys-Szulc E., Szolkiewicz M., Swierczynski J., Rutkowski B. Up-regulation of liver Pcsk9 gene expression as a possible cause of hypercholesterolemia in experimental chronic renal failure. Mol. Cell Biochem. 2016, 411:281-287.
5. Lopez D. PCSK9: an enigmatic protease. Biochim. Biophys. Acta 2008, 781:184-191.
6. Lambert G., Charlton F., Rye K.A., Piper D.E. Molecular basis of PCSK9 function. Atherosclerosis 2009, 203:1-7.
7. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. J. Lipid Res. 2012, 53:2515-2524.
8. Stein E.A., Swergold G.D. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr. Atheroscler. Rep. 2013, 15:310.
9. Seidah N.G., Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. Berl. 2007, 85:685-696.
10. Urban D., Pöss J., Böhm M., Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol. 2013, 62:1401-1408.
11. Abujrad H., Mayne J., Ruzicka M., Cousins M., Raymond A., Cheesman J., Taljaard M., Sorisky A., Burns K., Ooi T.C. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis 2014, 233:123-129.
12. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., Davignon J., Lambert M. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin. Chem. 2009, 55:1637-1645.
13. Soutar A.K. Unexpected roles for PCSK9 in lipid metabolism. Curr. Opin. Lipidol. 2011, 22:192-196.
14. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 2009, 94:2537-2543.
15. Chan D.C., Hamilton S.J., Rye K.A., Chew G.T., Jenkins A.J., Lambert G., Watts G.F. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes. Metab. 2010, 12:752-756.
16. Le May C., Kourimate S., Langhi C., Chetiveaux M., Jarry A., Comera C., Collet X., Kuipers F., Krempf M., Cariou B., Costet P. Proprotein convertase subtilisin kexintype 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29:684-690.
17. Lambert G., Jarnoux A.L., Pineau T., Pape O., Chetiveaux M., Laboisse C., Krempf M., Costet P. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 2006, 147:4985-4995.
18. Druce I., Abujrad H., Ooi T.C. PCSK9 and triglyceride-rich lipoprotein metabolism. J. Biomed. Res. 2015, 29:429-436.
19. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem. 2009, 284:28885-28895.
20. Shende V.R., Wu M., Singh A.B., Dong B., Kan C.F., Liu J. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice. J. Lipid Res. 2015, 56:801-809.
21. Hussain M.M., Shi J., Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 2003, 44:22-32.
22. Dai K., Hussain M.M. NR2F1 disrupts synergistic activation of the MTTP gene transcription by HNF-4α and HNF-1α. J. Lipid Res. 2012, 53:901-908.
23. Armendariz A.D., Krauss R.M. Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr. Opin. Lipidol. 2009, 20:106-111.
24. Xu R.X., Liu J., Li X.L., Li S., Zhang Y., Jia Y.J., Sun J., Li J.J. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. J. Transl. Med. 2015, 87:13.
25. Swierczynski J., Korczynska J., Szolkiewicz M., Karbowska J., Kochan Z., Nieweglowski T., Kusiak E., Rutkowski B. Low leptin mRNA level in adipose tissue and normoleptinemia in experimental chronic renal failure. Exp. Nephrol. 2001, 9:54-59.
26. Turyn J., Stojek M., Swierczynski J. Up-regulation of stearol-CoA desaturase 1 and elongase 6 genes expression in rat lipogenic tissues by chronic food restriction and chronic food restriction/refeeding. Mol. Cell Biochem. 2010, 345:181-188.
27. Man Z.W., Hirashima T., Mori S., Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushima fatty rats, a non-insulin-dependent diabetes model. Metabolism 2000, 49:108-114.
28. Tietge U.J., Bakillah A., Maugeais C., Tsukamoto K., Hussain M., Rader D.J. Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. 1999, 40:2134-2139.
29. Stafford J.M., Yu F., Printz R., Hasty A.H., Swift L.L., Niswender K.D. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion. Diabetes 2008, 57:1482-1490.
30. Lee H.B., Blaufox M.D. Blood volume in the rat. J. Nucl. Med. 1985, 26:172-176.
31. Zelewski M., Swierczyński J. The effect of clofibrate feeding on the NADP-linked dehydrogenases activity in rat tissue. Biochim. Biophys. Acta 1983, 758:152-157.
32. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 62:156-159.
33. Winer J., Jung C.K., Shackel I., Williams P.M. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 1999, 270:41-49.
34. Moon Y.A., Liang G., Xie X., Frank-Kamenetsky M., Fitzgerald K., Koteliansky V., Brown M.S., Goldstein J.L., Horton J.D. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 2012, 15:240-246.
35. Bar-Tana J. Hypolipidemia induced by PPARalpha agonists: HNF-4alpha as an alternative to PPARalpha. Curr. Opin. Investig. Drugs 2004, S5:941-946.
36. Troutt J.S., Alborn W.E., Cao G., Konrad R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J. Lipid Res. 2010, 51:345-351.
37. Hayhurst G.P., Lee Y.H., Lambert G., Ward J.M., Gonzalez F.J. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell Biol. 2001, 21:1393-1403.
38. Yin L., Ma H., Ge X., Edwards P.A., Zhang Y. Hepatic hepatocyte nuclear factor 4αis essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler. Thromb. Vasc. Biol. 2011, 31. 328-236.
39. Liang J.J., Oelkers P., Guo C., Chu P.C., Dixon J.L., Ginsberg H.N., Sturley S.L. Overexpression of human diacylglycerol acyltransferase 1, acyl-CoA:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. J. Biol. Chem. 2004, 279:44938-44944.
40. Liu Y., Millar J.S., Cromley D.A., Graham M., Crooke R., Billheimer J.T., Rader D.J. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice. Biochim. Biophys. Acta 2008, 1781:97-104.
41. Olofsson S.O., Boren J., Apolipoprotein B. a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J. Intern. Med. 2005, 258:395-410.
42. Szolkiewicz M., Nieweglowski T., Korczynska J., Sucajtys E., Stelmanska E., Goyke E., Swierczynski J., Rutkowski B. Upregulation of fatty acid synthase gene expression in experimental chronic renal failure. Metabolism 2002, 51:1605-1610.
43. Korczynska J., Stelmanska E., Nogalska A., Szolkiewicz M., Goyke E., Swierczynski J., Rutkowski B. Upregulation of lipogenic enzymes genes expression in white adipose tissue of rats with chronic renal failure is associated with higher level of sterol regulatory element binding protein-1. Metabolism 2004, 53:1060-1065.
44. Ryffel G.U. Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J. Mol. Endocrinol. 2001, 27:11-29.
45. Zhong W., Mirkovitch J., Darnell J.E. Tissue-specific regulation of mouse hepatocyte nuclear factor 4 expression. Mol. Cell Biol. 1994, 14:7276-7284.
46. Leighton J.K., Joyner J., Zamarripa J., Deines M., Davis R.A. Fasting decreases apolipoprotein B mRNA editing and the secretion of small molecular weight apoB by rat hepatocytes: evidence that the total amount of apoB secreted is regulated post-transcriptionally. J. Lipid Res. 1990, 31:1663-1668.
47. Shih D.Q., Dansky H.M., Fleisher M., Assmann G., Fajans S.S., Stoffel M. Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII),lipoprotein(a), and triglyceride levels. Diabetes 2000, 49:832-837.
48. Ouguerram K., Chetiveaux M., Zair Y., Costet P., Abifadel M., Varret M., Boileau C., Magot T., Krempf M. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1448-1453.
49. Chan D.C., Lambert G., Barrett P.H., Rye K.A., Ooi E.M., Watts G.F. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin. Chem. 2009, 55:2049-2052.
50. Kappelle P.J., Lambert G., Dahlback B., Nielsen L.B., Dullaart R.P. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis 2011, 214:492-494.